Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Parasympathetic cardiac dysfunction in Amyotrophic Lateral Sclerosis
Neuromuscular and Clinical Neurophysiology (EMG)
P10 - Poster Session 10 (8:00 AM-9:00 AM)
10-015
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease affecting the upper and lower motor neurons. Diffuse neuronal affection has been observed in more frequent neurological diseases of degenerative etiology. There are isolated and sometimes contradictory studies addressing cardiac dysautonomia in ALS. Both orthostatic hypotension (sympathetic nervous system) and reduced RR interval variability (parasympathetic nervous system) are associated with a higher morbimortality.

Study the presence of cardiac dysautonomia in ALS patients.

Demographic variables, ALS-FRS and MRC scores and forced vital capacity (FVC) were registered in 20 ALS patients (with definite or probable diagnosis according to El Escorial Revisited criteria) attending a regular neurological control. We performed dynamometry, orthostatic testing and manually evaluated the RR interval variability in resting, deep breathing and post Valsalva maneuver electrocardiograms. All patients signed the informed consent approved by the hospital’s ethics committee. Logistic regression was used to address the relationship between cardiac parasympathetic dysautonomia and the independent relevant variables.
The mean age was 52 years (SD 13.79), with 75% of male patients and 85% of spinal onset. The mean ALS-FRS and FVC scores were 25.65 (SD 10.55) and 67% (SD 21). Only one patient had orthostatic hypotension while 12 (58.8%) showed reduced RR interval variability, with a strong tendency of association with age and not any other variable.
Parasympathetic cardiac dysautonomia was very frequent in ALS patients. Larger studies are needed to confirm this finding since its diagnosis could help to tailor treatment and follow up in order to reduce other possible causes of morbimortality in ALS patients.
Authors/Disclosures
Cecilia Quarracino Benchetrit, MD
PRESENTER
Mrs. Quarracino Benchetrit has nothing to disclose.
Natalia Bohorquez Morera Natalia Bohorquez Morera has nothing to disclose.
Francisco Capani, MD,PhD (CAECHIS-UAI-CONICET, Av Montes de Oca 745, CABA) Dr. Capani has nothing to disclose.
Santiago Perez-Lloret The institution of Santiago Perez-Lloret has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ELEA LAboratories.
Gabriel Rodriguez Gabriel Rodriguez has nothing to disclose.